PartnershipApr 22, 2026, 07:57 PM
Exicure Partners with Adbiotech for Burixafor Combination Therapies
AI Summary
Exicure, Inc. announced a co-development agreement with Korea-based Adbiotech Co., Ltd. to explore combination therapies utilizing Burixafor (GPC-100). The collaboration will evaluate Burixafor in indications such as sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and manage clinical and regulatory strategy, building on Burixafor's successful Phase 2 trial in multiple myeloma.
Key Highlights
- Exicure partnered with Adbiotech for co-development of Burixafor combination therapies.
- Collaboration focuses on sickle cell disease, acute myeloid leukemia, and solid tumors.
- Adbiotech will conduct in vivo studies and support preclinical validation.
- Exicure will provide Burixafor and lead clinical and regulatory strategy.
- Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma.